Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2022-02-25
Target enrollment:
Participant gender:
Summary
This phase II trial investigates the how well acalabrutinib and obinutuzumab work in treating
patients with chronic lymphocytic leukemia (CLL). Acalabrutinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab
may induce changes in body's immune system and may interfere with the ability of tumor cells
to grow and spread. Giving acalabrutinib and obinutuzumab may help to control disease
progression in CLL patients who have not received treatment for CLL.